RxDoctor Payments Data

Bianca Persaud, MD

Internal Medicine · Brooklyn, NYNPI 1962723924

Payments from drug & device makers

$3,865in general payments, 2019–2025

Across 206 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$440
  • Pfizer$303
  • Amgen$263
  • AstraZeneca$208
  • Boehringer Ingelheim$200
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,850100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,865 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$49,122
Medicare patients
124
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$198,540
JardianceEmpagliflozin99$137,962
RybelsusSemaglutide51$92,310
EliquisApixaban84$88,781
FarxigaDapagliflozin Propanediol65$72,591
MounjaroTirzepatide36$55,569
TrulicityDulaglutide21$32,963
JanuviaSitagliptin Phosphate29$30,167
Synjardy XrEmpagliflozin/Metformin Hcl19$24,870
XareltoRivaroxaban28$23,639
MyrbetriqMirabegron29$19,852
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,693
Tresiba Flextouch U-100Insulin Degludec22$12,749
Repatha SureclickEvolocumab11$11,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,122$290,850168 claims
Boehringer IngelheimJardiance, Synjardy Xr$200$162,832118 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$208$92,00898 claims
PfizerEliquis$303$88,78184 claims
Lilly USA, LLCMounjaro, Trulicity$440$88,53257 claims
MerckJanuvia$30$30,16729 claims
Johnson & JohnsonXarelto$37$23,63928 claims
Astellas Pharma US IncMyrbetriq$150$19,85229 claims
GSKTrelegy Ellipta, Shingrix$199$13,84731 claims
BayerKerendia$76$10,66516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →